metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Streptococcus agalactiae altamente resistente a fluoroquinolonas
Journal Information
Vol. 24. Issue 9.
Pages 562-563 (November 2006)
Share
Share
Download PDF
More article options
Vol. 24. Issue 9.
Pages 562-563 (November 2006)
Originales breves
Full text access
Streptococcus agalactiae altamente resistente a fluoroquinolonas
Streptococcus agalactiae highly resistant to fluoroquinolones
Visits
6964
Elisenda Miróa, Montserrat Rebolloa, Alba Riveraa,b, M. Teresa Álvarezc, Ferrán Navarroa,b, Beatriz Mirelisa,b,
Corresponding author
bmirelis@santpau.es

Correspondencia: Dra. B. Mirelis. Departamento de Microbiología. Hospital de la Santa Creu i Sant Pau. Avda. Sant Antoni M. Claret, 167. 08025 Barcelona. España.
, Pere Colla,b
a Servicio de Microbiología. Hospital de la Santa Creu i Sant Pau. Barcelon. España
b Unidad de Microbiología. Departamento de Genética y Microbiología. Universidad Autónoma de Barcelona. Barcelon. España
c Unidad de Enfermedades Infecciosas. Hospital de la Santa Creu i Sant Pau. Barcelona. España
This item has received
Article information
Antecedentes

Streptococcus agalactiae se mantiene sensible a la penicilina, si bien se ha descrito un incremento en la resistencia a otras familias de antimicrobianos como macrólidos y más raramente fluoroquinolonas.

Métodos y resultados

Entre 2003 y 2004 se detectaron dos cepas de S. agalactiae resistentes a fluoroquinolonas, que presentaron mutaciones en parC (Ser79 → Phe) y gyrA (Glu85 → Ala o Glu85 → Lys).

Conclusión

Se describen por primera vez en España cepas de S. agalactiae altamente resistentes a fluoroquinolonas.

Palabras clave:
Streptococcus agalactiae
Fluoroquinolonas
parC
gyrA
Background

Streptococcus agalactiae remains susceptible to penicillin; nevertheless, an increase in the resistance to other antimicrobial families, such as macrolides and more rarely fluoroquinolones, has been described.

Methods

and results. From 2003 to 2004, two fluoroquinolone-resistant S. agalactiae strains were detected. The strains presented one mutation in parC (Ser79 → Phe) and an additional mutation in gyrA (Glu85 → Ala or Glu85 → Lys).

Conclusion

This study describes the first S. agalactiae strains highly resistant to fluoroquinolones in Spain.

Key words:
Streptococcus agalactiae
Fluoroquinolones
parC
gyrA
Full text is only aviable in PDF
Bibliografía
[1.]
A. Schuchat.
Epidemiology of group B streptococcal disease in the United States: shifting paradigms.
Clin Microbiol Rev, 11 (1998), pp. 497-513
[2.]
J. Liñares, A.G. De la Campa, R. Pallarés.
Fluoroquinolone resistance in Streptococcus pneumoniae.
N Engl J Med, 341 (1999), pp. 1546-1547
[3.]
T.A. Davies, R. Goldschmidt, S. Pfleger, M. Loeloff, K. Bush, D.F. Sahm, et al.
Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000).
J Antimicrob Chemother, 52 (2003), pp. 168-175
[4.]
S.S. Richter, K.P. Heilmann, S.E. Beekmann, N.J. Miller, C.L. Rice, G.V. Doern.
The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Clin Infect Dis, 40 (2005), pp. 225-235
[5.]
S. Malhotra-Kumar, C. Lammens, S. Chapelle, C. Mallentjer, J. Weyler, H. Goossens.
Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes.
J Antimicrob Chemother, 55 (2005), pp. 320-325
[6.]
Y. Kawamura, H. Fujiwara, N. Mishima, Y. Tanaka, A. Tanimoto, S. Ikawa, et al.
First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC.
Antimicrob Agents Chemother, 47 (2003), pp. 3605-3609
[7.]
W. Wehbeh, R. Rojas-Díaz, X. Li, N. Mariano, L. Grenner, S. Segal-Maurer, et al.
Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance.
Antimicrob Agents Chemother, 49 (2005), pp. 2495-2497
[8.]
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests-Eigth edition. Approved standard M2-A8: NCCLS, Wayne, Pa, USA; 2003.
[9.]
J.J. González, A. Andreu, Spanish Group for the Study of Perinatal Infection from the Spanish Society for Clinical Microbiology and Infectious Diseases.
Multicenter study of the mechanisms of resistance and clonal relationships of Streptococcus agalactiae isolates resistant to macrolides, lincosamides, and ketolides in Spain.
Antimicrob Agents Chemother, 49 (2005), pp. 2525-2527
[10.]
M.E. Jones, D.F. Sahm, N. Martín, S. Scheuring, P. Heisig, C. Thornsberry, et al.
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.
Antimicrob Agents Chemother, 44 (2000), pp. 462-466
Copyright © 2006. Elsevier España S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos